OREXIGEN THERAPEUTICS INC's ticker is OREXXXXX and the CUSIP is 686164104. A total of 66 filers reported holding OREXIGEN THERAPEUTICS INC in Q2 2016. The put-call ratio across all filers is 4.92 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2016 | $1,446,000 | -37.1% | 3,363,185 | -17.7% | 0.00% | 0.0% |
| Q1 2016 | $2,300,000 | -59.5% | 4,087,748 | +23.8% | 0.00% | -50.0% |
| Q4 2015 | $5,679,000 | -32.4% | 3,301,767 | -17.0% | 0.00% | -33.3% |
| Q3 2015 | $8,396,000 | -41.0% | 3,979,635 | +38.5% | 0.00% | -40.0% |
| Q2 2015 | $14,224,000 | -37.7% | 2,873,592 | -1.4% | 0.01% | -37.5% |
| Q1 2015 | $22,824,000 | +63.2% | 2,914,945 | +26.3% | 0.01% | +60.0% |
| Q4 2014 | $13,982,000 | +161.7% | 2,307,319 | +84.0% | 0.01% | +150.0% |
| Q3 2014 | $5,342,000 | +885.6% | 1,253,935 | +1330.1% | 0.00% | – |
| Q2 2014 | $542,000 | +54.0% | 87,680 | +61.9% | 0.00% | – |
| Q1 2014 | $352,000 | +177.2% | 54,167 | +141.5% | 0.00% | – |
| Q4 2013 | $127,000 | -36.5% | 22,434 | -31.0% | 0.00% | – |
| Q3 2013 | $200,000 | -28.3% | 32,514 | -31.9% | 0.00% | – |
| Q2 2013 | $279,000 | – | 47,726 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management II, LLC | 5,427,559 | $2,334,000 | 1.60% |
| Scale Management, LLC | 1,312,575 | $564,000 | 1.34% |
| Foresite Capital Management III, LLC | 2,542,575 | $1,093,000 | 0.75% |
| BVF INC/IL | 5,252,100 | $2,258,000 | 0.48% |
| TIVERTON ASSET MANAGEMENT LLC | 45,313 | $4,261,000 | 0.18% |
| Baupost Group | 22,268,399 | $9,575,000 | 0.13% |
| Rhenman & Partners Asset Management AB | 1,200,000 | $516,000 | 0.09% |
| NEA Management Company, LLC | 370,900 | $1,595,000 | 0.08% |
| SAMLYN CAPITAL, LLC | 6,160,417 | $2,649,000 | 0.06% |
| Palo Alto Investors LP | 1,673,024 | $719,000 | 0.05% |